FDA extends Capricor's deramiocel review deadline to November 2026
Tweet Send to a Friend
Capricor Therapeutics (NASDAQ: CAPR) announced that the U.S. Food and Drug Administration has extended the Prescription Drug User Fee Act ...
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE
This is a premium only article. To continue reading this and other premium stock market news articles please sign-in or upgrade to StreetInsider.com Premium below (Free Trial) LEARN MORE


